Thursday, July 9, 2026

pharma · Minimal Residual Disease · Pancreatic Ductal Adenocarcinoma · ELTX

Elicio Therapeutics

Elicio Therapeutics drug portfolio — 0 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Boston, USA HQ
47 Employees
Public company Type
ELTX · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Employees
47
Programs
2
Drugs
0
Patents
4
Intelligence · Drug Pipeline

Elicio Therapeutics pipeline

Portfolio lens on 0 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Elicio Therapeutics drug portfolio — 0 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

No drugs indexed yet

We have not linked approved or pipeline drugs to this company profile yet.

View clinical projects →